Roic AI
Search
/
Search
/
Pricing
Sign inSign up

You're using the beta version. You're using the beta version of the new website.

SummaryFinancialsRatiosTranscriptsClassic View

Footer

Found an error or have an idea?
or write us an email to [email protected]

Company

  • About
  • Pricing
  • Blog

Support

  • Knowledge Base
  • FAQ

Legal

  • Privacy Policy

© 2023 Roic AI, Inc. All rights reserved.

Business
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
  1. United States Stocks
  2. •

    Healthcare
  3. •

    Biotechnology
Innoviva, Inc. logo

Innoviva, Inc.

HVE GR

HVE GRInnoviva, Inc.GRGR
FIGI: BBG000FQTHC3

Company News

  • Dow Jones Newswires

    a month ago

    Innoviva Appoints Stephen Basso As Chief Financial Officer >INVA

  • Dow Jones Newswires

    2 months ago

    Innoviva 2Q EPS 2c >INVA

  • MarketWatch.com

    4 months ago

    FDA approves Innoviva's bacterial pneumonia treatment

  • Dow Jones Newswires

    5 months ago

    Innoviva 1Q EPS 42c >INVA

  • Dow Jones Newswires

    5 months ago

    Innoviva Announces Retirement Of Board Chairman >INVA

  • Dow Jones Newswires

    5 months ago

    Innoviva Shares Rise 7% After Pneumonia Drug's Approval by FDA Committee

  • Dow Jones Newswires

    5 months ago

    Innoviva Shares Halted as FDA Panel Reviews Sulbactam-Durlobactam >INVA

  • Barron's

    2 years ago

    Theravance Stock Drops on Covid-19 Therapy Disappointment

12.40

EUR
+0.40
(+3.33%)
Innoviva, Inc.
HVE:GR
(Greece Composite)

Recent

price

12.40

P/E

ratio

3.62

div

yld

- -

ROIC.AI

Legends:
Stock price
0.38
Beta (1.0 Market)
% total return 09/27
Stock
S&P500
YTD
0.84
- -
3Y
31.15
- -
5Y
- -
- -
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
USD
0.36
0.38
0.39
0.34
0.30
1.49
0.05
0.08
0.47
1.21
2.03
2.59
- -
3.32
4.78
4.76
4.26
Revenue per ShareRevenue per Share
-2.64
-1.53
-1.35
-1.16
-1.41
-0.20
-1.67
-1.50
-0.16
0.54
1.25
3.92
- -
2.21
3.24
3.07
3.43
Basic EPS, GAAPBasic EPS, GAAP
-1.89
-1.64
-0.93
-1.05
-1.12
-1.44
-2.12
-1.17
0.09
0.55
1.33
2.22
- -
3.09
4.42
2.90
1.30
Free Cash Flow per Basic ShareFree Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
0.51
0.76
0.01
0.00
0.00
- -
- -
- -
- -
- -
Dividend per ShareDividend per Share
-15.34
-19.61
-17.38
-14.93
-15.37
-13.55
-13.49
-14.38
-14.73
-15.05
-14.70
-10.91
-9.33
-7.11
-6.55
-2.95
-2.58
Book Value per ShareBook Value per Share
-1.08
-2.57
-2.94
-0.28
-1.02
1.58
1.57
-1.92
-2.99
-3.26
-2.38
1.57
3.38
5.99
7.56
4.14
4.55
Tangible Book Value per ShareTangible Book Value per Share
60
61
63
72
82
91
102
112
115
110
107
101
- -
101
82
70
68
Basic Weighted Avg SharesBasic Weighted Avg Shares
22
23
24
24
25
136
5
8
54
134
217
261
261
337
392
331
290
Sales/Revenue/TurnoverSales/Revenue/Turnover
-766.13
-380.09
-329.10
-323.34
-447.69
-9.58
-3,549.03
-402.34
58.54
81.60
88.26
93.47
94.39
95.35
95.72
62.47
36.20
Operating Margin (%)Operating Margin (%)
4
7
6
6
8
7
8
12
14
14
14
14
14
14
14
6
22
Depreciation ExpenseDepreciation Expense
-160
-94
-85
-84
-115
-19
-171
-168
-19
60
134
395
157
224
266
214
233
Net Income, GAAPNet Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
17.99
17.06
17.17
23.24
26.61
Effective Tax Rate (%)Effective Tax Rate (%)
-727.19
-405.45
-349.97
-346.21
-470.56
-13.66
-3,587.66
-1,997.68
-34.77
44.57
61.76
151.36
60.26
66.63
67.84
64.56
80.35
Profit Margin (%)Profit Margin (%)
79
166
123
276
199
231
399
238
202
187
190
193
426
336
308
405
284
Working CapitalWorking Capital
0
173
173
173
173
173
288
726
748
716
599
383
377
386
395
540
447
LT DebtLT Debt
-66
-135
-189
-22
-87
155
299
-223
-343
-353
-243
159
342
608
526
566
555
Total EquityTotal Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
32.04
31.10
32.47
14.96
7.31
Return on Invested Capital (%)Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-22.15
-42.17
-164.63
90.75
94.42
Return on Capital (%)Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)Return on Common Equity (%)
Capital Structure
USD

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
98
1
1
LT Borrowings
540
445
445
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
66
65
Market Capitalization
917
741
830
Working Capital
USD

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
444
296
324
Cash, Cash Equivalents & STI
291
144
173
Accounts Receivable, Net
64
76
81
Inventories
56
50
47
Total Current Liabilities
39
38
39
Payables & Accruals
4
1
31
ST Debt
98
1
1
Deferred Revenue
2
2
3
Growth Rates
USD

•

in mil. unless spec.
(avg. rate of change)
10 years
5 years
1 year
Sales/Revenue/Turnover
79.89%
10.03%
-15.56%
Net Income, GAAP
-82.56%
35.28%
-19.55%
Free Cash Flow
57.50%
13.18%
-44.35%
Total Cash Common Dividend
- -
- -
- -
Total Equity
-8.57%
4.31%
7.60%
Quarterly Revenue
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
86
101
98
108
392
2022
90
108
67
66
331
2023
76
81
- -
- -
- -
Quarterly Earnings Per Share
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
0.93
1.01
1.04
0.15
3.24
2022
0.23
0.01
3.81
-0.98
3.07
2023
0.51
0.02
- -
- -
- -
Quarterly Dividends Per Share
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -